Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GOSS
STRONG SELLREMOVEGossamer Bio, Inc. · Healthcare · United States · $79M · Avg Vol: $3M/d
Clinical-stage biopharmaceutical company with high development risk and no current commercial revenues.
COMPANY DESCRIPTION
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, and developing immunology, inflammation, and oncology therapies. The company's lead clinical candidate, seralutinib, is an inhaled PDGFR inhibitor being developed for the treatment of pulmonary arterial hypertension (PAH). Gossamer Bio leverages a highly experienced drug development team to target high-value, unmet medical needs within the cardiopulmonary and inflammatory disease spaces.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 115M | 48M | -57.7% |
| EPS | -2.71 | -1.18 | -0.25 | -0.75 | — |
| Shares | 94M | 225M | 227M | 234M | +147.5% |
| Debt | 226M | 212M | 203M | 203M | -3.5% |
| Equity | 12M | 63M | 29M | -123M | 56.3% |
| Op CF | -187M | -159M | -3M | -171M | — |
| Inv CF | -1M | -111M | 29M | 156M | — |
| Fin CF | 117M | 190M | -11M | 6M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GOSS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc.(you) | $79M | 9 | STRONG SELL |
| FLNA | Filana Therapeutics, Inc. | $75M | 11 | STRONG SELL |
| 2257.HK | Sirnaomics Ltd. | $82M | 7 | STRONG SELL |
| ANIX | Anixa Biosciences, Inc. | $91M | 7 | STRONG SELL |
| AARD | Aardvark Therapeutics, Inc. | $92M | 7 | STRONG SELL |
| BMEA | Biomea Fusion, Inc. | $100M | 10 | STRONG SELL |
| CGTX | Cognition Therapeutics, Inc. | $107M | 9 | STRONG SELL |
| ATYR | aTyr Pharma, Inc. | $82M | 3 | STRONG SELL |
| ACRV | Acrivon Therapeutics, Inc. | $70M | 14 | STRONG SELL |
| GANX | Gain Therapeutics, Inc. | $86M | 3 | STRONG SELL |
Peer medians: ROE -22.6% · P/E 25.3x · Gross margin 44.3%